Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V 2 ) Therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE
    • Publication Information:
      Publication: 2021- : Basel, Switzerland : MDPI
      Original Publication: Toronto : Multimed, c1994-
    • Subject Terms:
      Leukemia, Lymphocytic, Chronic, B-Cell* ; Lymphoma* ; Splenic Neoplasms*/drug therapy ; Splenic Neoplasms*/pathology; Bortezomib/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic ; Humans ; Sulfonamides
    • Abstract:
      Standard treatment regimens for the management of patients with refractory splenic marginal zone lymphoma (SMZL) are currently unavailable. Here, we report a case of SMZL, which, after failing multiple therapeutics, demonstrated an impressive clinical response to combined Venetoclax and Velcade (V 2 ), a treatment combination currently being investigated in the setting of refractory multiple myeloma. We also report a unique histopathology and mutational profile that may have important implications for the characterization and prognosis of SMZL.
    • References:
      Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):791-798. (PMID: 31648953)
      Leuk Lymphoma. 2014 Jul;55(7):1463-70. (PMID: 24050506)
      Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):75-85. (PMID: 25108679)
      Br J Haematol. 2019 Jun;185(5):874-882. (PMID: 30919940)
      Oncologist. 2013;18(2):190-7. (PMID: 23345547)
      J Clin Oncol. 2009 Oct 20;27(30):5023-30. (PMID: 19770386)
      Br J Haematol. 2012 Nov;159(3):322-8. (PMID: 23016878)
      Am J Surg Pathol. 2001 Oct;25(10):1268-76. (PMID: 11688461)
      Lancet Oncol. 2003 Feb;4(2):95-103. (PMID: 12573351)
      Ann Lymphoma. 2021 Mar;5:. (PMID: 33829216)
      Expert Opin Investig Drugs. 2021 Jan;30(1):25-38. (PMID: 33295827)
      Blood. 2019 May 2;133(18):1964-1976. (PMID: 30850381)
      Blood Adv. 2020 Nov 24;4(22):5773-5784. (PMID: 33227125)
      Haematologica. 2012 Apr;97(4):595-8. (PMID: 22102703)
      J Hematop. 2013 Mar;6(1):11-18. (PMID: 25937841)
      Semin Cancer Biol. 2013 Dec;23(6):410-21. (PMID: 24060900)
      J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753)
      Blood. 2020 Dec 3;136(23):2628-2637. (PMID: 32785666)
      Best Pract Res Clin Haematol. 2017 Mar - Jun;30(1-2):139-148. (PMID: 28288709)
      Br J Haematol. 2018 Dec;183(5):755-765. (PMID: 30407629)
      Haematologica. 2005 Jun;90(6):856-8. (PMID: 15951303)
      Cancers (Basel). 2020 Jun 04;12(6):. (PMID: 32512867)
      Leukemia. 2008 Mar;22(3):487-95. (PMID: 18094718)
      Drugs Context. 2019 Oct 09;8:212574. (PMID: 31645879)
      Ann Oncol. 2018 Sep 1;29(9):1932-1938. (PMID: 30060083)
      Rev Bras Hematol Hemoter. 2017 Apr - Jun;39(2):146-154. (PMID: 28577652)
      Arch Pathol Lab Med. 2011 Aug;135(8):964-6. (PMID: 21809985)
      Cancer. 2006 Jul 1;107(1):125-35. (PMID: 16700034)
      J Clin Oncol. 2005 Jan 20;23(3):468-73. (PMID: 15659492)
      Semin Hematol. 2010 Apr;47(2):143-7. (PMID: 20350661)
      Hematol Oncol. 2008 Jun;26(2):114. (PMID: 18271062)
      Ann Oncol. 2015 Nov;26(11):2329-35. (PMID: 26400898)
      Leuk Lymphoma. 2014 Aug;55(8):1854-60. (PMID: 24206091)
      Lancet Oncol. 2020 Dec;21(12):1630-1642. (PMID: 33129376)
      Blood. 2017 Apr 20;129(16):2224-2232. (PMID: 28167659)
      J Clin Oncol. 2019 May 10;37(14):1188-1199. (PMID: 30897038)
    • Contributed Indexing:
      Keywords: Bortezomib (Velcade); Venetoclax; chemotherapy refractory; progression without transformation; relapsed/refractory (R/R); splenic marginal zone lymphoma (SMZL)
    • Accession Number:
      0 (Bridged Bicyclo Compounds, Heterocyclic)
      0 (Sulfonamides)
      69G8BD63PP (Bortezomib)
      N54AIC43PW (venetoclax)
    • Publication Date:
      Date Created: 20220623 Date Completed: 20220624 Latest Revision: 20220812
    • Publication Date:
      20221213
    • Accession Number:
      PMC9221762
    • Accession Number:
      10.3390/curroncol29060328
    • Accession Number:
      35735437